| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We found vascular endothelial growth factor (VEGF) is a potential factor for the development of multiple organ dysfunction syndrome (MODS) in sepsis. And VEGF has organ and tissue specific role and function in MODS in sepsis. In the current project, we used various pharmacological interventions for the treatment of MODS from early sepsis, some drugs like endothelin blockade, TNF-alpha blockade, protease activated receptor 2 (PAR2) blockade, VEGF receptor antagonist, ultra-short acting beta blocker as therapeutics for MODS in sepsis.
In this report, we are providing in details how downregulated VEGF in heart tissue in early sepsis can be reversed with the treatment of an ultra-short acting beta blocker, landiolol hydrochloride. Indeed, myocardial dysfunction is a common complication in sepsis which is associated with decreased myocardial level of VEGF. Beta blocker plays crucial role in normalizing the sepsis-mediated decreased cardiac VEGF levels.
|
